SMI Expanded
1.678,72
PKT
+6,26
PKT
+0,37
%
Werbung
Analysen zu SMI Expanded-Werten
Datum | Rating | Analyst | |
---|---|---|---|
20.01.12 | Givaudan reduce | Nomura | |
20.01.12 | Meyer Burger Technology kaufen | Geldbrief | |
20.01.12 | Novartis buy | Nomura | |
20.01.12 | Swiss Re neutral | Nomura | |
20.01.12 | Swiss Re hold | Société Générale Group S.A. (SG) | |
19.01.12 | Roche overweight | Barclays Capital | |
20.01.12 | Novartis overweight | J.P. Morgan Cazenove | |
19.01.12 | Holcim hold | Deutsche Bank AG | |
19.01.12 | Swiss Re buy | Sarasin Research | |
19.01.12 | ABB (Asea Brown Boveri) verkaufen | National-Bank AG | |
19.01.12 | ABB (Asea Brown Boveri) outperform | Sanford C. Bernstein and Co., Inc. | |
19.01.12 | UBS overweight | Morgan Stanley | |
18.01.12 | Holcim neutral | Exane-BNP Paribas SA | |
18.01.12 | UBS underperform | Exane-BNP Paribas SA | |
18.01.12 | UBS underperform | Exane-BNP Paribas SA | |
18.01.12 | Novartis halten | Independent Research GmbH | |
18.01.12 | Clariant hold | Vontobel Research | |
18.01.12 | SGS SA buy | Vontobel Research | |
18.01.12 | Tecan (N) hold | Vontobel Research | |
18.01.12 | Novartis hold | Vontobel Research | |
17.01.12 | Givaudan overweight | J.P. Morgan Cazenove | |
17.01.12 | Galenica neutral | Sarasin Research | |
17.01.12 | Nestlé buy | UBS AG | |
17.01.12 | SGS SA neutral | Sarasin Research | |
17.01.12 | Holcim neutral | Sarasin Research | |
17.01.12 | Novartis buy | Nomura | |
17.01.12 | SGS SA buy | Vontobel Research | |
17.01.12 | Barry Callebaut hold | Vontobel Research | |
17.01.12 | Galenica hold | Vontobel Research | |
17.01.12 | ABB (Asea Brown Boveri) outperform | Credit Suisse Group | |
16.01.12 | UBS neutral | Banc of America Securities-Merrill Lynch | |
16.01.12 | UBS buy | Banc of America Securities-Merrill Lynch | |
16.01.12 | Nestlé buy | UBS AG | |
16.01.12 | Partners Group overweight | Morgan Stanley | |
16.01.12 | Nestlé hold | Vontobel Research | |
16.01.12 | Lindt hold | Vontobel Research | |
16.01.12 | Holcim hold | Vontobel Research | |
16.01.12 | Novartis buy | WestLB AG | |
16.01.12 | Zurich Insurance buy | Citigroup Corp. | |
16.01.12 | Holcim neutral | Exane-BNP Paribas SA |